Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Dermatol ; 24(6): 424-9, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25776770

ABSTRACT

Primary cutaneous large B-cell lymphomas, leg type (PCLBCL/LT) are primary cutaneous B-cell lymphoma (PCBCL) with an intermediate prognosis. Therefore, antracycline-based polychemotherapy combined with rituximab has been recommended as first-line treatment. Yet, despite this regimen, the 5-year survival rate remains 50-66% only. Angiogenesis, the formation of a vascular network, is essential for the pathogenesis of nodal lymphomas. So far, no study has analysed angiogenesis and its key factors in PCLBCL/LT. The present study was aimed at characterizing angiogenesis in PCLBCL/LT to identify the angiogenic molecules as potential therapeutic targets. The intra-tumoral microvessel density (MVD) was assessed by immunohistochemical studies of CD20 and CD31. The MVD was higher in PCLBCL/LT compared with indolent PCBCL. Analyses of open-source microarray data showed correlation between the angiogenic molecule angiopoietin-2 (Ang-2) and pan-endothelial cell markers. ELISA studies determined a shift between Ang-2 and Ang-1 towards Ang-2 in the peripheral blood of PCLBCL/LT patients. Immunofluorescence costainings against the Ang receptor Tie2/angiogenic integrins/CD34 revealed that the vasculature in both aggressive and indolent PCBCL tumors harbours an endothelial cell subpopulation with reduced expression of Tie2. In contrast, the alternative Ang-2 binding partners, angiogenic integrins, are strongly expressed in PCBCL. In line with these findings, downstream targets of Ang-2-integrin signalling, that is phosphorylation of focal adhesion kinase at Tyr397, and sprouting angiogenesis are enhanced in PCLBCL/LT. Our data present Ang-2 as a promising therapeutic target and anti-angiogenic therapy as a new line in treatment of PCLBCL/LT as a hitherto intractable disease.


Subject(s)
Angiopoietin-2/metabolism , Lymphoma, B-Cell/metabolism , Neovascularization, Pathologic/metabolism , Skin Neoplasms/blood supply , Skin Neoplasms/metabolism , Angiopoietin-2/genetics , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Gene Expression Regulation, Neoplastic/genetics , Gene Expression Regulation, Neoplastic/physiology , Humans , Integrins/metabolism , Lymphoma, B-Cell/genetics , Microvessels/pathology , Phosphorylation , Signal Transduction/genetics , Signal Transduction/physiology , Skin Neoplasms/genetics
2.
Eur J Immunol ; 36(11): 2894-903, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17048269

ABSTRACT

An adaptive immune response implies expansion of activated T cells and subsequent elimination to maintain homeostasis in a process called activation-induced cell death. Some cells, however, differentiate into memory cells and ensure a strong secondary immune response. To analyze the apoptosis phenotype of memory T cells on a cellular and molecular level, we have established an in vitro model of T cell activation and generation of cells phenotypically and functionally similar to memory cells. These long-term cultured T cells show a CD95-resistant phenotype, although they are still sensitive towards TCR/CD3-mediated apoptosis. Biochemical analysis revealed that these cells shift from CD95 type I (direct signaling from the receptor) during the effector phase to CD95 type II cells (dependent on the mitochondrial amplification loop). Moreover, their mitochondria are protected, probably due to high expression levels of Bcl-x(L) and Bcl-2. Thus, our data suggest a mechanism how memory T cells acquire resistance towards bystander cell death via the CD95 system.


Subject(s)
Apoptosis , Cell Culture Techniques , Fas Ligand Protein/pharmacology , T-Lymphocytes/drug effects , fas Receptor/physiology , Cells, Cultured , Humans , Immunologic Memory , Lymphocyte Activation , Mitochondria/drug effects , Mitochondria/physiology , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-bcl-2/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Up-Regulation , bcl-X Protein/analysis , bcl-X Protein/metabolism
3.
Blood ; 107(10): 3933-9, 2006 May 15.
Article in English | MEDLINE | ID: mdl-16403915

ABSTRACT

The HTLV-1 transactivator protein Tax is essential for malignant transformation of CD4 T cells, ultimately leading to adult T-cell leukemia/lymphoma (ATL). Malignant transformation may involve development of apoptosis resistance. In this study we investigated the molecular mechanisms by which HTLV-1 Tax confers resistance toward CD95-mediated apoptosis. We show that Tax-expressing T-cell lines derived from HTLV-1-infected patients express elevated levels of c-FLIP(L) and c-FLIP(S). The levels of c-FLIP correlated with resistance toward CD95-mediated apoptosis. Using an inducible system we demonstrated that both resistance toward CD95-mediated apoptosis and induction of c-FLIP are dependent on Tax. In addition, analysis of early cleavage of the BH3-only Bcl-2 family member Bid, a direct caspase-8 substrate, revealed that apoptosis is inhibited at a CD95 death receptor proximal level in Tax-expressing cells. Finally, using siRNA we directly showed that c-FLIP confers Tax-mediated resistance toward CD95-mediated apoptosis. In conclusion, our data suggest an important mechanism by which expression of HTLV-1 Tax may lead to immune escape of infected T cells and, thus, to persistent infection and transformation.


Subject(s)
Apoptosis/physiology , Gene Products, tax/physiology , Human T-lymphotropic virus 1/physiology , Intracellular Signaling Peptides and Proteins/genetics , fas Receptor/physiology , Base Sequence , CASP8 and FADD-Like Apoptosis Regulating Protein , DNA Primers , Gene Deletion , Gene Products, tax/genetics , Humans , Jurkat Cells , Kinetics , Recombinant Fusion Proteins/metabolism , bcl-X Protein/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...